6th Immunotherapy Innovation Congress in China

In recent years, with the rapid development of Immunology and Molecular Biology and the soaring growth of market size, immunotherapy has become a nonnegligible hot spot with attention from pharmaceutical industry professionals across the globe. It is the discovery of various new targets from globe, the launch of new technologies and the successful experiments of clinical cases that makes immunotherapy gradually come into public attention. The green pass and breakthrough designation of immunotherapy policy at home and abroad also means that the world will mark the peak of the vigorous development of immunotherapy.

Currently, many domestic immunotherapeutic drugs have declared INA and some are still in the clinical stage, but there are still many problems and challenges: domestic regulations on cell immunotherapy are ambiguous large-scale clinical trials and standardized clinical evaluation can’t be conducted; domestic immunotherapy drug is lacking in innovation and still follows the footstep of leading players’ research and development; single immunotherapy can’t conquer tumor cells due to the complexity of tumor micro-environment.

Therefore, on the basis of the successful holding of previous five conferences, the 6th Immunotherapy Innovation Congress in China will invite more than 50 domestic and overseas well-known experts, scholars and R&D scientists from leading enterprises to specifically focus on industrial hot issues and challenges. From three aspects of preclinical, clinical and industrialization, ITIC will interpret domestic and foreign immunotherapy policies; share the latest clinical cases and data of immunotherapy from home and abroad; discuss the clinical application of various kinds of immunotherapy combination; analyze the domestic and overseas market-layout and competition for immunotherapy and so on. Meanwhile, it will also roundly cover the global main immunotherapeutic technology for cancer, autoimmune diseases and chronic infectious diseases, and have a thorough discussion on drug R&D on new immune targets, pre/clinical development and industrialization solutions.

The 21st century is the century of life science.

The Bio-energy Park and Bio-manufacturing Park will have total area of 5 square kilometers, Wuhan National Bio-industry Base (i.e. Biolake), located at Wuhan East-Lake National Innovation Demonstration Area, is the second state-level industrial cluster built by Optics Valley of China, targeting “100-billion-RMB industry”.

During the past 5 years of development, Biolake adhered to the international industry standard and global R&D frontier. Six platforms, including technical support, public service, incubation, information sharing, investment & financing and talent introduction, have been built. Eight Global Fortune 500 Enterprises, 13 domestic listed companies, 258 domestic and oversea high-level teams settled down. The growth rate of major economic indicators is over 40%. Realized a “five-five” goal: 5 major parks formed; over 5 million square meters have been constructed; clustered 546 enterprises; annual total revenue exceeded 50 billion RMB; and 5 world-class innovation achievements have been industrialized. Biolake has established an international benchmark for the bio-industry of China.It is estimated that, by 2018, at the 10th anniversary, the total revenue of Biolake will reach over 200 billion RMB and become a world-class bio-industry cluster.

Biolake, your new opportunity and new start!